Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ST6GAL1 | P15907 | 7/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719007 | 0.88 | POLB (0.43) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL718788 | 0.81 | POLB (0.37) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL18817573 | 0.80 | POLB (0.37) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL7522179 | 0.78 | POLB (0.43) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL7522185 | 0.78 | POLB (0.43) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL7524507 | 0.77 | POLB (0.46) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL5200171 | 0.74 | POLB (0.40) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL7518632 | 0.72 | POLB (0.31) | POLGPOLBST6GAL1 | |
| SCHEMBL888343 | 0.72 | LMNA (0.38) | POLGPOLBST6GAL1CACNA1FLMNA | |
| SCHEMBL5200194 | 0.71 | POLB (0.37) | POLGPOLBST6GAL1CACNA1FLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452026-B1 | REACTING THREO-3-AMINO-1,2-DIOL COMPOUND WITH SULFONYLATING AGENT AND EPOXIDATION TO FORM 3-AMINO-1,2-EPOXY COMPOUND | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020058825-A1 | Process for producing optically active threo-3-amino-1,2-epoxy compounds | SAGAWA YUKIHIRO (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376685-B1 | SULFONYLATION; CYCLIZATION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-1052257-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE THREO-3-AMINO-1,2-EPOXY COMPOUNDS | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058825-A1 | Process for producing optically active threo-3-amino-1,2-epoxy compounds | DAO, DHPS, ALKBH3 | POLG 2200/4885POLB 1705/4885ST6GAL1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.